Atrion (NASDAQ: ATRI) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.8%. MiMedx Group does not pay a dividend. Atrion pays out 26.6% of its earnings in the form of a dividend. Atrion has increased its dividend for 15 consecutive years.
Institutional & Insider Ownership
59.0% of Atrion shares are owned by institutional investors. Comparatively, 69.2% of MiMedx Group shares are owned by institutional investors. 23.1% of Atrion shares are owned by insiders. Comparatively, 12.4% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Atrion and MiMedx Group’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings & Valuation
This table compares Atrion and MiMedx Group’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Atrion has higher earnings, but lower revenue than MiMedx Group. Atrion is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Atrion and MiMedx Group, as provided by MarketBeat.com.
||Strong Buy Ratings
MiMedx Group has a consensus price target of $17.00, indicating a potential upside of 20.65%. Given MiMedx Group’s higher probable upside, analysts plainly believe MiMedx Group is more favorable than Atrion.
Risk & Volatility
Atrion has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
Atrion beats MiMedx Group on 9 of the 16 factors compared between the two stocks.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
About MiMedx Group
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.